大连职业技术学院 - 学籍科
该站暂未设置description...
该站暂未设置keywords...
百度权重
百度移动
360权重
搜狗权重
站点URL: http://xj.dlvtc.edu.cn · 站点编号:76663 · 加入时间:0000-00-00 00:00:00
做上本站友情链接,在您站上点击一次,即可自动秒收录并自动排在本站第一位!<a href="https://www.9sl.cn/" target="_blank">玖收录</a>
域名(xj.dlvtc.edu.cn)由网友主动性提交被玖收录整理收录的,本页最后更新时间为:2023-05-19 09:14:05,玖收录仅提供xj.dlvtc.edu.cn的基础信息并免费向广大游客展示,该站IP地址为,该站打开速度为,该站的百度权重为、百度手机权重为、百度收录为条、360收录为条、搜狗收录为条、谷歌收录为条、百度来访流量大约在之间、百度手机端来访流量大约在之间、xj.dlvtc.edu.cn的备案号是、备案人叫、被百度收录的关键词有个、手机端关键词有个、迄今为止已经创建,其内容不代表本站赞成被显示该站点的内容或立场,相关资料: txt下载、docx下载、pdf下载、rar下载、zip下载,本页地址:https://www.9sl.cn/links/0a0decb71ee73196f5c7.html。

WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity,foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.